購物車 
-
貝西洛索單抗
- names：
Besilesomab
- CAS號(hào)：
537694-98-7
MDL Number： - MF(分子式)： MW(分子量)：
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| DBK502149-500mg | 500mg | ￥ 0.00 | ￥ 0.00 | Get quote | ￥ 0.00 | |||
| DBK502149-100mg | 100mg | ￥ 0.00 | ￥ 0.00 | Get quote | ￥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝，敬請垂詢
- 收藏商品 商品點(diǎn)評 加入購物車 立即購買
| 中文別名 | 貝西洛索單抗 |
| 英文別名 | Besilesomab |
| CAS號(hào) | 537694-98-7 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | |
| 分子量 Molecular Weight | |
| 溶解度Solubility | |
| 性狀 | Solid |
| 儲(chǔ)藏條件 Storage conditions |
貝西洛索單抗使用注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害。
3.取樣品的移液槍頭需及時(shí)更換，必要時(shí)為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時(shí)選用稱量紙，并無風(fēng)處取藥和稱量以免揚(yáng)撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時(shí)盡量采用多個(gè)藥勺分別使用，使用后清洗干凈。
6.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害。
3.取樣品的移液槍頭需及時(shí)更換，必要時(shí)為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時(shí)選用稱量紙，并無風(fēng)處取藥和稱量以免揚(yáng)撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時(shí)盡量采用多個(gè)藥勺分別使用，使用后清洗干凈。
6.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 產(chǎn)品說明 | Organic Acids |
| Introduction | |
| Application1 | Nonspecific cross-reacting antigens (NCA) is the name of a collection of highly glycosylated bacterial binding receptors expressed on human granulocytes and other tissues1. In particular, these glycoprotein receptors are members of the immunoglobulin supergene family and are related structurally to carcinoembryonic antigen (CEA)1. CEA is found naturally in the human body and its expression may be increased in both cancer and non-cancerous (benign) circumstances.Besilesomab is subsequently a murine immunoglobulin monoclonal antibody of IgG1 isotype designed to recognise and bind specifically to NCA-95, or nonspecific cross-reacting antigen 95, an epitope found expressed on the cell membranes of granulocytes and granulocyte precursorsLabel.When radiolabelled with sodium pertechnetate (Tc99m) solution to develop technetium (Tc99m) besilesomab solution, this radiolabelled medicine is injected into patients where the monoclonal antibody carries it to target CEA on target granulocytesLabel. When large numbers of CEA expressing granulocytes gather to the site of an infection, the radioactive monoclonal antibodies will also accumulate at such sites, where it can be detected by diagnostic scanningLabel. The resultant images show where the radioactive besilesomab has accumulated, locating areas affected by osteomyelitis, infection, or inflammationLabel.Furthermore, it is believed that the besilesomab accumulation is predominantly passive (via increased vascular permeability) and only partially active (via migration of human granulocytes carrying besilesomab to the infection/inflammation location) since only 10% to 20% of the injected radio-diagnostic agent binds in vivo to human circulating granulocytes4. Specific binding of besilesomab to activated granulocytes that have already migrated to sites of infection/inflammation might be the primary part of the detection signal4.TargetActionsOrganismNCarcinoembryonic antigenNot AvailableHumans |
| Application2 | |
| Application3 |
| 警示圖 | |
| 危險(xiǎn)性 | |
| 危險(xiǎn)性警示 | warning |
| 安全聲明 | |
| 安全防護(hù) | |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食如，做好安全防護(hù) |
對不起，暫無產(chǎn)品評價(jià)！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
胞插件.png)
細(xì)胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細(xì)胞培養(yǎng)板行業(yè)面臨的核心痛點(diǎn)是：常規(guī)TC處理后表面親水角隨時(shí)間衰減，影響長期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
胞培養(yǎng)板.jpg)
細(xì)胞培養(yǎng)耗材關(guān)鍵性能
細(xì)胞培養(yǎng)板的水接觸角作為表面潤濕性的核心指標(biāo)，直接影響細(xì)胞貼壁、增殖、分化及功能表達(dá)，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價(jià)陽離子的偏好。它對二價(jià)...
2025/11/4 14:22:46
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
